A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Cantor initiated Amgen (NASDAQ:AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Family Heart Foundation unveiled the Cholesterol Connect program for LDL-C Awareness Day, aiming to make it easier for people ...

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...